ReviewRenal failure2026
Tandem extracorporeal blood purification therapies for sepsis and acute kidney injury in critically ill children: a state-of-the-art review.
Review in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tandem extracorporeal blood purification and support therapies integrate established therapies such as continuous renal replacement therapies (CRRT), extracorporeal membrane oxygenation (ECMO), intermittent or prolonged renal replacement therapies with emerging adsorptive, immunomodulatory, and organ-support technologies. These approaches are increasingly applied in critically ill children with complex multi-organ dysfunction, particularly in the settings of severe sepsis, hyperinflammatory syndromes, acute kidney injury, liver failure, and refractory cardiorespiratory compromise. Despite growing clinical adoption, most tandem applications remain off-label in pediatrics, with evidence largely limited to case reports, single-center experiences, and small observational cohorts, and with few standardized protocols to guide practice.This state-of-the-art review synthesizes available pediatric and relevant adult literature to examine the mechanistic rationale, technical integration, clinical indications, and reported outcomes of tandem extracorporeal strategies beyond conventional CRRT-ECMO-therapeutic plasma exchange combinations. We focus on under-reported and emerging modalities, including hemoperfusion and adsorptive hemofilters integrated with CRRT or ECMO, leukapheresis combined with renal replacement or extracorporeal life support, selective cytopheretic and immunomodulatory devices, extracorporeal liver support platforms, and novel miniaturized and translational technologies. Practical considerations related to circuit configuration, anticoagulation strategies, and extracorporeal volume are discussed, alongside safety considerations unique to pediatric populations. While early experiences suggest feasibility and potential benefit, current evidence is insufficient to establish definitive efficacy or survival benefit. This review highlights critical knowledge gaps, implementation barriers, and research priorities, and aims to support the development of standardized, evidence-based guidelines to promote safe, effective, and reproducible use of tandem extracorporeal therapies in pediatric critical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.